TIMOTHY NEWTON

Founder and Chief Executive Officer, Reflection Therapeutics

Tim has led Reflection Therapeutics since it’s foundation in 2018, developing an anti inflammatory cell therapy to treat neurodegeneration. The first indication for this platform technology is ALS. In founding Reflection Therapeutics he secured dilutive and non-dilutive funding to develop this idea into an in vivo proof of concept therapeutic. This fundraising has included awards from Innovate UK, Medcity, LifeArc and the Babraham Research Campus, where Reflection Therapeutics are based.

Tim has over a decades experience in neurodegeneration research, including post-docs at the University of Cambridge and the Alzheimer’s Research UK Drug Discovery Institute, publishing peer reviewed articles on neurodegeneration and drug discovery in journals such as Brain and The British Journal of Pharmacology. Prior to founding Reflection Therapeutics Tim held a company creation role at Deep Science Ventures. Tim has an MBiochem from the University of Oxford, and a MRes and PhD in Medicine from the University of Cambridge.

 LIVE ONLINE

23 September 2021

CATCH UP ON DEMAND